Your browser is no longer supported. Please, upgrade your browser.
Sangamo Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.26 Insider Own17.01% Shs Outstand145.40M Perf Week-10.56%
Market Cap842.24M Forward P/E- EPS next Y-1.39 Insider Trans-1.10% Shs Float120.90M Perf Month-22.28%
Income-181.40M PEG- EPS next Q-0.34 Inst Own53.10% Short Float7.39% Perf Quarter-30.64%
Sales108.50M P/S7.76 EPS this Y-6.00% Inst Trans0.03% Short Ratio5.96 Perf Half Y-41.69%
Book/sh2.79 P/B2.13 EPS next Y-5.30% ROA-21.20% Target Price18.89 Perf Year-61.86%
Cash/sh2.98 P/C1.99 EPS next 5Y- ROE-39.90% 52W Range6.03 - 16.79 Perf YTD-20.93%
Dividend- P/FCF- EPS past 5Y-9.10% ROI-26.10% 52W High-64.68% Beta1.51
Dividend %- Quick Ratio3.40 Sales past 5Y24.50% Gross Margin- 52W Low-1.66% ATR0.45
Employees413 Current Ratio3.40 Sales Q/Q-50.50% Oper. Margin- RSI (14)27.71 Volatility6.07% 5.95%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume1.00 Prev Close6.40
ShortableYes LT Debt/Eq0.00 EarningsNov 04 BMO Payout- Avg Volume1.50M Price5.93
Recom2.10 SMA20-20.62% SMA50-29.02% SMA200-39.42% Volume1,503,372 Change-7.34%
May-04-21Initiated RBC Capital Mkts Outperform $22
Jan-07-21Resumed Guggenheim Neutral $16
Jan-06-21Initiated Stifel Hold $16
Dec-16-20Resumed H.C. Wainwright Buy $25
Sep-08-20Initiated BofA Securities Buy $20
Jul-07-20Initiated SunTrust Buy $22
Aug-26-19Initiated H.C. Wainwright Buy $16
Nov-14-18Downgrade JP Morgan Overweight → Neutral
Nov-09-18Downgrade Guggenheim Buy → Neutral
Oct-10-18Initiated Guggenheim Buy
Jun-20-18Initiated BofA/Merrill Buy $24
Nov-15-17Upgrade Piper Jaffray Neutral → Overweight
Jun-22-17Resumed Jefferies Buy $17
Nov-01-16Downgrade Wedbush Outperform → Neutral $30 → $4
Oct-19-16Downgrade Piper Jaffray Overweight → Neutral
Dec-04-15Initiated Wells Fargo Outperform
Oct-23-15Resumed Jefferies Buy
May-03-13Initiated BioLogic Equity Research Sell
Feb-23-11Reiterated JMP Securities Mkt Outperform $9 → $12
Jul-29-10Reiterated Wedbush Outperform $12 → $13
Jan-13-22 01:38PM  
Jan-06-22 08:00AM  
Jan-04-22 05:00PM  
Dec-20-21 05:29PM  
Dec-13-21 10:54AM  
Dec-12-21 04:30PM  
Dec-10-21 09:34AM  
Nov-22-21 07:00AM  
Nov-18-21 05:54PM  
Nov-09-21 08:30AM  
Nov-08-21 10:13AM  
Nov-04-21 10:01PM  
Oct-28-21 04:30PM  
Oct-27-21 03:03PM  
Oct-11-21 03:29PM  
Aug-31-21 08:30AM  
Aug-10-21 05:21AM  
Aug-09-21 04:30PM  
Aug-05-21 05:45PM  
Jul-30-21 12:15PM  
Jul-29-21 04:30PM  
Jul-28-21 03:03PM  
Jun-14-21 11:51AM  
Jun-07-21 10:22AM  
May-24-21 04:15PM  
May-21-21 08:30AM  
May-12-21 01:52PM  
May-05-21 05:01AM  
May-04-21 05:25PM  
May-03-21 04:30PM  
Apr-27-21 04:30PM  
Mar-25-21 08:30AM  
Mar-17-21 04:30PM  
Mar-16-21 03:26PM  
Mar-09-21 05:10AM  
Mar-01-21 11:10AM  
Feb-26-21 09:34AM  
Feb-25-21 06:30PM  
Feb-24-21 04:01PM  
Feb-18-21 04:15PM  
Feb-17-21 04:15PM  
Feb-01-21 04:05PM  
Jan-07-21 11:25PM  
Jan-06-21 04:10PM  
Jan-05-21 08:00AM  
Dec-15-20 10:54AM  
Dec-14-20 08:43AM  
Dec-10-20 02:03PM  
Dec-07-20 07:00AM  
Nov-30-20 06:42AM  
Nov-24-20 11:39AM  
Nov-05-20 08:00AM  
Nov-04-20 11:02PM  
Oct-28-20 04:15PM  
Oct-16-20 11:36AM  
Oct-07-20 06:45AM  
Oct-05-20 11:41AM  
Sep-28-20 08:30AM  
Sep-15-20 10:48AM  
Sep-11-20 08:30AM  
Sep-10-20 12:11PM  
Sep-02-20 04:15PM  
Sep-01-20 03:47PM  
Aug-20-20 09:43AM  
Aug-19-20 12:19PM  
Aug-10-20 08:30AM  
Aug-05-20 06:35PM  
Aug-03-20 12:49PM  
Jul-30-20 07:00AM  
Jul-29-20 04:15PM  
Jul-27-20 06:07PM  
Jul-09-20 07:43AM  
Jun-24-20 08:00AM  
Jun-19-20 12:22PM  
Jun-18-20 09:44AM  
Jun-16-20 08:36AM  
Jun-15-20 10:40PM  
Jun-14-20 06:00AM  
Jun-11-20 05:14PM  
May-29-20 09:00AM  
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; BIVV003, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease; ST-400, a cell therapy, which is in Phase I/II Thales clinical trials for the treatment of transfusion dependent beta thalassemia. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, an anti-CD19 CAR-T cell therapy for the treatment of cancer. ST-101 gene therapy for phenylketonuria. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIOGEN INC.10% OwnerDec 28Sale8.512,76423,52224,152,466Dec 30 05:12 PM
BIOGEN INC.10% OwnerDec 27Sale8.566005,13624,155,230Dec 28 08:11 AM
BIOGEN INC.10% OwnerDec 23Sale8.5581,187694,53024,155,830Dec 28 08:11 AM
BIOGEN INC.10% OwnerDec 09Sale8.5623,660202,54124,237,017Dec 10 04:08 PM
BIOGEN INC.10% OwnerDec 08Sale8.6475,814654,82824,260,677Dec 09 04:08 PM
BIOGEN INC.10% OwnerDec 07Sale8.5252,178444,43724,336,491Dec 09 04:08 PM
BIOGEN INC.10% OwnerDec 02Sale8.511,87415,94324,388,669Dec 03 04:09 PM
BIOGEN INC.10% OwnerDec 01Sale8.527306,22324,390,543Dec 03 04:09 PM
BIOGEN INC.10% OwnerNov 26Sale8.6028,884248,43424,391,273Nov 30 04:20 PM
LOEB GARYEVP, General Counsel & Sec.Mar 23Option Exercise11.0211,981132,031100,762Mar 25 07:19 PM
LOEB GARYEVP, General Counsel & Sec.Mar 23Sale13.1317,524230,04283,238Mar 25 07:19 PM